The National Marrow Donor Program

As the number of successful marrow transplants has increased, the lack of HLA‐identical sibling donors for 60 to 70 percent of transplant candidates has become a serious problem. Pilot studies established that marrow transplantation between phenotypically HLA‐identical, unrelated individuals can be accomplished successfully. Therefore, the National Marrow Donor Program was established to develop a large file of volunteer marrow donors and to serve as a center for the coordination of the donor search and donor‐recipient matching processes. By November 1991, 63 months after the program was established, 457,205 potential marrow donors typed for HLA‐A and ‐B antigens had agreed to be listed in the marrow donor registry. A donor search had been initiated for 8481 patients. At least one potential donor matched for at least three of the four HLA‐A and ‐B antigens was located for 99.8 percent of patients. Among the 3156 searches that were completed, 940 (29.8%) resulted in a transplant. The median time in which to locate a matched donor, complete all predonation evaluations, and obtain donor consent was 208 days. The most common diagnosis in patients who underwent transplantation was chronic myelogenous leukemia (42.0%). When this analysis was completed in November 1991, the National Marrow Donor Program was operating a national network of 99 donor centers and 53 transplant centers. The donor file was increasing rapidly, and a follow‐ up system was in place to determine the effects of donation on the donors and the outcome in the patients who underwent transplantation. This national network of donor and transplant centers exists and is now facilitating unrelated‐donor marrow transplants. The National Marrow Donor Program made it possible to locate donors for many patients in need of a transplant and helped to determine the role of unrelated‐ donor marrow transplants in the treatment of many diseases.

[1]  P V Holland,et al.  Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program. , 1993, Blood.

[2]  J. Hansen,et al.  Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. , 1993, The New England journal of medicine.

[3]  R. Champlin.  Allogeneic bone marrow transplantation using unrelated donors. , 1993, Leukemia & lymphoma.

[4]  M. Pepe,et al.  Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. , 1991, Transplantation.

[5]  S. Feig,et al.  Bone marrow transplantation using unrelated donors for patients with advanced leukemia or bone marrow failure. , 1990, Transplantation.

[6]  J. McCullough,et al.  HLA class I and II antigen phenotypes of North American Indians from Minnesota: implications for marrow transplants using unrelated donors , 1990, Transfusion.

[7]  P. Beatty,et al.  Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases. , 1990, Blood.

[8]  S. Gore,et al.  Unrelated donor marrow transplantation between 1977 and 1987 at four centers in the United Kingdom. , 1990, Transplantation.

[9]  R. Truitt,et al.  Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. , 1990, The New England journal of medicine.

[10]  B. Camitta,et al.  Bone marrow transplantation for children with severe aplastic anemia: use of donors other than HLA-identical siblings. , 1989, Blood.

[11]  B. DuPont.  Nomenclature for factors of the HLA system, 1987. Decisions of the Nomenclature Committee on Leukocyte Antigens, which met in New York on November 21-23, 1987. , 1989, Human immunology.

[12]  P. Beatty,et al.  The use of unrelated bone marrow donors in the treatment of patients with chronic myelogenous leukemia: experience of four marrow transplant centers. , 1989, Bone marrow transplantation.

[13]  E. Scott,et al.  Effectiveness of a regional bone marrow donor program. , 1988, JAMA.

[14]  D. Hussey,et al.  Allogeneic marrow grafting with partially mismatched, unrelated marrow donors. , 1988, Blood.

[15]  J. Hansen,et al.  PROBABILITY OF FINDING HLA‐MATCHED UNRELATED MARROW DONORS , 1988, Transplantation.

[16]  E. Scott,et al.  Unrelated donor bone marrow transplantation therapy for chronic myelogenous leukemia. , 1987, Blood.

[17]  Apperley,et al.  Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anemia and leukemia. , 1986, Blood.

[18]  A. Rimm,et al.  Increasing utilization of bone marrow transplantation. , 1986, Transplantation.

[19]  R. Aster,et al.  Recruitment of unrelated persons as bone marrow donors. A preliminary experience , 1986, Transfusion.

[20]  E. Scott,et al.  Development and operation of a program to obtain volunteer bone marrow donors unrelated to the patient , 1986, Transfusion.

[21]  R. Storb,et al.  Marrow transplantation from related donors other than HLA-identical siblings. , 1985, The New England journal of medicine.

[22]  B. Camitta,et al.  BONE MARROW TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA USING A PHENOTYPICALLY HLA‐IDENTICAL, SBCOMPATIBLE UNRELATED DONOR , 1983, Transplantation.

[23]  E. Gordon-Smith,et al.  Bone-marrow transplantation for severe aplastic anaemia using histocompatible unrelated volunteer donors. , 1982, British medical journal.

[24]  J. McCullough.  Bone marrow transplantation from unrelated volunteer donors: summary of a conference on scientific, ethical, legal, financial, and other practical issues , 1982, Transfusion.

[25]  R. Storb,et al.  Transplantation of marrow from an unrelated donor to a patient with acute leukemia. , 1980, The New England journal of medicine.

[26]  J. Hansen,et al.  Reconstitution in severe combined immunodeficiency by transplantation of marrow from an unrelated donor. , 1977, The New England journal of medicine.

[27]  M. Torres,et al.  Nomenclature for factors of the HLA system. , 2011, Bulletin of the World Health Organization.

[28]  F. Bach,et al.  TREATMENT OF SEVERE COMBINED IMMUNODEFICIENCY WITH BONE-MARROW FROM AN UNRELATED, MIXED-LEUCOCYTE-CULTURE-NONREACTIVE DONOR , 1975, The Lancet.